Early Results of Prostate Cancer Drug Clinical Trial Appear Encouraging, Nymox Says

Early Results of Prostate Cancer Drug Clinical Trial Appear Encouraging, Nymox Says
Nymox Pharmaceutical Corp. recently announced the 18-month results from its 40-month Phase 2 clinical trial (NX03-0040) of fexapotide triflutate (NX-1207) in localized prostate cancer. The results revealed the study endpoints were met and that cancer progression was improved in the groups of patients who were treated with fexapotide. NX-1207 is a novel drug that can be administered by a urologist in an office procedure that takes a few minutes, does not require any type of anesthesia or catheterization, and involves little or no pain or discomfort. The trial that began in February 2013 at 28 clinical sites in the U.S. was designed to evaluate the safety and efficacy of a single injection of NX-1207 for the treatment of biopsy-confirmed low-risk localized (T1c) prostate cancer in 147 patients currently undergoing active surveillance. Study participants were randomized either to treatment with a single intraprostatic injection of NX-1207 (2.5 mg. or 15 mg.) followed by active surveillance, or to no treatment (continued active surveillance). Results of the 18-month clinical outcomes of a single injection of fexapotide included:
  • Undetectable cancer post-treatment in the region of the prostate where the baseline cancer was detected;
  • Reduction of 75.5 percent in biopsy-proven prostate cancer Gleason upgrades in patients treated with fexapotide 15 mg. compared to control; reduction of 71.7 percent in prostate cancer Gleason upgrades in patients treated with fexapotide compared to controls;
  • A re
    Subscribe or to access all post and page content.

Tagged , , , , .

Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *